Skip to Main Content
June 30, 2020

Health Law Daily

Gilead Announces Pricing For Remdesivir

  • June 30, 2020

The Washington Post (6/29, Denham) reports that Gilead Sciences on Monday said that a typical course of treatment with remdesivir for a [COVID-19] patient will cost “U.S. hospitals $3,120 for the typical patient with private insurance.” The US government announced that “it had secured nearly all of the company’s supply of the drug for use in U.S. hospitals through September, with a contract for 500,000 treatment courses.” Gilead will make the drug available to “other developed countries” at a 25% discount. It will also be produced in developing countries by generic manufacturers “at a substantially lower cost.” The Post also reports that an analysis by the Institute for Economic and Clinical Review showed that “Gilead could recover its costs by distributing the drug for as little as $1 to $60 per dose, or $100 to $160 per dose if all of the company’s 2020 costs are taken into account.”
      Reuters (6/29, Erman, Burger, Maddipatla) reports Gilead set a price of “$2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.” Reuters says that price is “slightly below the range of $2,520 to $2,800 suggested last week by U.S. drug pricing research group the Institute for Clinical and Economic Review.” Gilead CEO Daniel O’Day “said the price is well below the value it provides given that early hospital discharges could save around $12,000 per patient in the United States.”
      The Wall Street Journal (6/29, Walker, Subscription Publication) reports the US government will pay $390 per dose, which is $2,340 for a short course or $4,290 for a longer course of treatment. Hospitals will be charged $520 per dose or $3,120 for a short treatment course.